Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
Phase 1
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00773188
A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 281
- Registration Number
- NCT00773331
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 209
- Registration Number
- NCT00773461
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳General Hospital of Chinese PLA; Department of Hematology, Beijing, China
🇨🇳Beijing Union Hospital, Beijing, China
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
Phase 2
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00773383
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Phase 4
Completed
- Conditions
- Chronic Renal Anemia
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2825
- Registration Number
- NCT00773513
- Locations
- 🇦🇺
Gosford Hospital; Renal, Gosford, New South Wales, Australia
🇭🇷General Hospital Josip Bencevic; Department of Haemodialysis, Slavonski Brod, Croatia
🇦🇺Renal Research Dr Simon Roger, Gosford, New South Wales, Australia
A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes
Not Applicable
Completed
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Device: Accu-Chek Spirit Insulin PumpDevice: Comparator insulin pump
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT00772356
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Phase 3
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT00770562
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Phase 2
Terminated
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT00760929
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada
🇺🇸North Shore University Health System, Glenview, Illinois, United States
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
Phase 1
Completed
- Conditions
- Peripheral Arterial Disease (PAD)
- Interventions
- Drug: placebo
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 72
- Registration Number
- NCT00760565
A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- Drug: tacrolimus, low doseDrug: tacrolimus, standard doseDrug: corticosteroids
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT00758602
© Copyright 2025. All Rights Reserved by MedPath